AAM names president, CEO

The Association for Accessible Medicines has a new president and CEO. The AAM board of directors has appointed Dan Leonard to head the organization beginning in September. He joins the generic drug and biosimilar industry trade group from the National Pharmaceutical Council, where he was president and CEO. 

AAM’s board has been searching for a new president and CEO since February when Chip Davis departed to lead the Healthcare Distribution Alliance, with senior vice president and general counsel Jeff Francer taking on additional duties. 

“We are confident that Dan will lead the association’s talented team to support our work with the administration and Congress to further secure the pharmaceutical supply chain and create market conditions that will ensure the long-term viability of the generic and biosimilars industry,” said Carol Lynch, president of Sandoz US, head of Sandoz North America and AAM board vice chair. 

At NPC, where he served for 12 years, Leonard used qualitative data development to offer policymakers a scientific foundation to inform their decisions about health care access and value. Before his time at NPC, he was executive vice president of advocacy and professional services at America’s Health Insurance Plans, the trade organization representing U.S. health insurers. Besides his time in trade organizations, Leonard also has experience as a communications and media professional who has worked in strategic communications, legislative management, politics and broadcast journalism.